# Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

> **NCT01080248** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT01080248
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2010-12
- **Final completion:** 2011-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Closed due to delay by GSK
- **Last updated:** 2015-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080248, "Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01080248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*